Item 1.01 Entry into a Material Definitive Agreement.
On July 16, 2009, Gilead Sciences, Inc. (Gilead) filed a Current Report on Form
8-K (the Original Report) disclosing that Gilead and its wholly owned
subsidiary, Gilead Sciences Limited, entered into a License and Collaboration
Agreement with Tibotec Pharmaceuticals (Tibotec). This Form 8-K/A is being filed
for the sole purpose of correcting a typographical error in the second paragraph
under Item 1.01 of the Original Report. The Original Report reported that Gilead
will pay up to €71,450,000 million of Tibotec's development costs for TMC-278
and such amount should have been €71,450,000.
Top of the Form
Add
GILD to Portfolio
Set Alert
Email to a
Friend